Entera Bio Accelerates Lead Osteoporosis Drug Phase 3 Trial by One Year
Summary
Entera Bio announced a significant acceleration for its lead drug candidate, EB613, an oral osteoporosis treatment. The company submitted a streamlined Phase 3 protocol to the FDA, which is expected to reduce enrollment requirements and bring topline results forward by approximately one year, now anticipated in the second half of 2028. This follows the FDA's prior alignment in July 2025 on bone mineral density (BMD) as a primary endpoint, a development also noted in recent news. For a company of Entera Bio's market capitalization, accelerating a pivotal Phase 3 trial by a full year is a highly material positive development, significantly impacting the drug's potential time to market and future revenue streams. Investors should watch for anticipated FDA feedback on the streamlined protocol in late April 2026, which will serve as the next key catalyst.
At the time of this announcement, ENTX was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.8M. The 52-week trading range was $0.98 to $3.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.